Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

EZH2 致癌失调为肺癌靶向治疗提供了机会

阅读：8

作者：Haikuo Zhang, Jun Qi, Jaime M Reyes, Lewyn Li, Prakash K Rao, Fugen Li, Charles Y Lin, Jennifer A Perry, Matthew A Lawlor, Alexander Federation, Thomas De Raedt, Yvonne Y Li, Yan Liu, Melissa A Duarte, Yanxi Zhang, Grit S Herter-Sprie, Eiki Kikuchi, Julian Carretero, Charles M Perou, Jacob B Reibel,

期刊：

Cancer Discovery

影响因子：

29.700

时间：

2016

起止号：

2016 Sep;6(9):1006-21.

doi：

10.1158/2159-8290.CD-16-0164

方法学：

研究方向：

肿瘤

疾病类型：

肺癌

Significance

EZH2 overexpression induces murine lung cancers that are similar to human NSCLC with high EZH2 expression and low levels of phosphorylated AKT and ERK, implicating biomarkers for EZH2 inhibitor sensitivity. Our EZH2 inhibitor, JQEZ5, promotes regression of these tumors, revealing a potential role for anti-EZH2 therapy in lung cancer. Cancer Discov; 6(9); 1006-21. ©2016 AACR.See related commentary by Frankel et al., p. 949This article is highlighted in the In This Issue feature, p. 932.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。